|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:affiliatedWith
|
non-nucleoside reverse transcriptase inhibitor
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AG03
|
|
gptkbp:brand
|
gptkb:Stocrin
gptkb:Sustiva
|
|
gptkbp:CASNumber
|
gptkb:154598-52-4
|
|
gptkbp:combinationProduct
|
gptkb:Atripla
|
|
gptkbp:combines
|
emtricitabine
tenofovir
|
|
gptkbp:contraindication
|
severe liver disease
pregnancy (first trimester)
|
|
gptkbp:developedBy
|
gptkb:DuPont
|
|
gptkbp:discoveredIn
|
1996
|
|
gptkbp:eliminationHalfLife
|
40-55 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:hasMolecularFormula
|
C14H9ClF3NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
efavirenz
|
|
gptkbp:interactsWith
|
gptkb:rifampicin
gptkb:St._John's_wort
anticonvulsants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 reverse transcriptase
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
gptkb:CYP2B6
liver
|
|
gptkbp:patentExpired
|
2013 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyRisk
|
teratogenic
|
|
gptkbp:proteinBinding
|
99.5%
|
|
gptkbp:PubChem_CID
|
57718
64139
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
anxiety
dizziness
rash
hepatotoxicity
insomnia
impaired concentration
vivid dreams
|
|
gptkbp:synonym
|
gptkb:EFV
|
|
gptkbp:UNII
|
JE6H2O27P8
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:NNRTIs
|
|
gptkbp:bfsLayer
|
5
|